Jared Baeten, MD, PhD

Gilead Sciences

Disclosure(s): Gilead Sciences: Employee, Stocks/Bonds

Poster(s):

• 1251 - 5-year outcomes of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment of HIV-1 in adults with high baseline HIV-1 RNA and/or low CD4 count in two Phase 3 randomized clinical trials
  Friday, October 21, 2022

  12:15 PM – 1:30 PM US ET

• 2079 - Comparison of Recency Assays to Estimate HIV Incidence in the SIENA (eStimating hIv incidEnce amoNg Agyw) Study in Uganda
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET